Apax Partners Buys Gerresheimer Plastics for $1.5B

Apax Partners has agreed to acquire Gerresheimer's Centor business and its global Primary Packaging Plastics division for approximately $1.5 billion. This strategic divestiture marks a significant move for Gerresheimer, allowing it to sharpen its focus on higher-margin pharmaceutical products and drug delivery systems, while creating a new, independent healthcare packaging entity under Apax's stewardship.

The transaction encompasses 16 manufacturing facilities and involves around 2,400 employees across nine countries. Centor, a key player in prescription medicine dispensing systems, particularly in the United States, along with the Primary Packaging Plastics business, which manufactures direct-contact plastic packaging for pharmaceuticals, generated combined revenues of roughly €570 million in the 2025 fiscal year. These businesses will be divested through separate transactions, with the Centor sale anticipated by the end of Gerresheimer's 2026 fiscal year and the plastics division expected to conclude in the first half of fiscal year 2027, pending regulatory approvals.

Gerresheimer intends to leverage the substantial cash infusion from these sales to significantly reduce its debt burden and optimize its capital structure. This deleveraging is projected to lower interest expenses and enhance financial flexibility, enabling greater investment in its core, higher-value offerings. The company is strategically pivoting towards specialized areas such as injectable drug packaging, medical devices, and advanced drug delivery systems, a segment experiencing robust growth driven by the increasing prevalence of biologic therapies and complex treatment regimens.

The divestiture aligns with Gerresheimer's broader transformation initiative aimed at boosting operational performance and free cash flow. By shedding these plastic packaging operations, the company can concentrate resources and expertise on sophisticated products like syringes, vials, cartridges, auto-injectors, and on-body devices, which demand stringent manufacturing standards and cater to the evolving needs of the pharmaceutical and biotechnology sectors. This strategic realignment positions Gerresheimer to capitalize on the expanding market for specialized drug administration solutions.

Apax Partners plans to establish the acquired businesses as a standalone healthcare packaging company, building on their established market presence. The private equity firm intends to inject further capital to fuel expansion, drive product innovation, and enhance manufacturing capabilities, particularly within the United States. Apax's expertise in corporate carve-outs will be instrumental in separating these operations from Gerresheimer and building the necessary infrastructure for an independent, agile organization capable of navigating the demanding healthcare packaging sector.

The healthcare packaging market is characterized by rigorous quality and regulatory demands, essential for ensuring the safety and efficacy of medications. Centor and the Primary Packaging Plastics business play a critical role in this ecosystem, supplying essential packaging solutions for millions of patients globally. This acquisition by Apax Partners underscores the strategic value and growth potential identified within this specialized segment of the packaging industry.